[1] 汤志奇, 龚婷.对比剂肾病的早期诊断新进展[J].临床肾脏病杂志,2016,16(5):317-319.
[2] 尤威, 戚晨良, 叶飞,等.尿中性粒细胞明胶酶相关脂质运载蛋白对对比剂肾病的早期诊断价值[J].中华心血管病杂志, 2016, 44(12):1024-1029.
[3] 李莹.肝细胞肝癌(HCC)病人行经动脉化学栓塞(TACE)术后对比剂肾病(CIN)的发生率[J].国际医学放射学杂志, 2014,37(4):396.
[4] 郭亭亭,刘芳.对比剂肾病的中西医防治[J].中西医结合心脑血管病杂志,2016,14(1):49,51.
[5] An JN, Yoo KD, Hwang JH,et al.Circulating tumor necrosis factor receptors 1 and 2 predict contrast-induced nephropathy and progressive renal dysfunction:a prospective cohort study [J].Nephrology(Carlton),2015, 20(8): 552-559.
[6] Kunak CS, Ugan RA, Cadirci E,et al.Nephroprotective potential of carnitine against glycerol and contrast-induced kidney injury in rats through modulation of oxidative stress, proinflammatory cytokines,and apoptosis [J].Br J Radiol,2016,89(1058):20140724.
[7] 叶锦棠, 张保翠, 罗健,等. 血肌酐正常人群中糖尿病与对比剂肾病的相关性研究[J].放射学实践, 2016, 31(2):123-125.
[8] 汪玉琴,罗长青,王玉梅,等.血清胱抑素C评估对比剂肾病的Meta分析[J].现代中西医结合杂志,2016,16(10):589-593.
[9] Gutiérrez-Escolano A, Santacruz-Vázquez E, Gómez-Pérez F. Dysregulated microRNAs involved in contrast-induced acute kidney injury in rat and human [J].Ren Fail,2015,37(9):1498-1506. |
2018, Vol. 35 
